Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358466 | 0.85 | DGAT1 (0.34) | DGAT1BRD4CREBBP | |
| SCHEMBL2358312 | 0.79 | DGAT1 (0.35) | DGAT1BRD4CREBBPMAPT | |
| SCHEMBL20706486 | 0.79 | DGAT1 (0.37) | DGAT1BRD4CREBBPPDE10A | |
| SCHEMBL2359234 | 0.74 | DGAT1 (0.35) | DGAT1BRD4CREBBPNPC1 | |
| SCHEMBL13521539 | 0.73 | DGAT1 (0.35) | DGAT1BRD4CREBBPMAPTPDE10A | |
| SCHEMBL12904171 | 0.72 | AURKA (0.46) | DGAT1BRD4CREBBP | |
| SCHEMBL12389652 | 0.72 | NPC1 (0.39) | BRD4CREBBPMAPTNPC1 | |
| SCHEMBL2315637 | 0.72 | DGAT1 (0.38) | DGAT1BRD4CREBBPMAPTPDE10A | |
| SCHEMBL25171887 | 0.71 | DUT (0.41) | DGAT1BRD4CREBBPMAPTNPC1 | |
| SCHEMBL13737232 | 0.71 | DGAT1 (0.34) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | DGAT1 2419/4885BRD4 1047/4885CREBBP 4379/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | DGAT1 2419/4885BRD4 1047/4885CREBBP 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.